Cardiology

Data show Black and White patients had a similar risk of MACE over a median 24.4-month follow-up.

Check out the latest cardiology case report from Brady Pregerson, MD. This report features a man in his mid-40s with epigastric pain but no reports of any shortness of breath, sweating, nausea, vomiting, chest pain, or other complaints. Can you determine the correct diagnosis?

From the pooled results of TRILOGY 1 and 2, data show 4 g/d of ω-3–PL/FFA reduced TG levels by 10.9% at 12 weeks and 12.7% at 26 weeks, relative to placebo.

A comparison of data from patients with mild to moderate COVID-19 provides insight into the long-term effects on cardiac, renal, pulmonary, and thrombotic function status.

The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was −11.0 mm Hg in the chlorthalidone group and −0.5 mm Hg in the placebo group.

A cross-sectional study of more than 1000 patients suggests presence of MACS in patients with benign adrenal tumors was associated with increased prevalence and severity of hypertension as well as an increase in the likelihood of requiring insulin therapy in type 2 diabetes.

In comparison to men, women with ASCVD were more likely to report being clinically depressed, have cost-related medication nonadherence, and have not seen a physician due to cost.

In older adults with atrial fibrillation, rivaroxaban was associated with a significantly increased risk of major ischemic or hemorrhagic events compared to apixaban.

Accurate results can be obtained rapidly with this intuitive whole blood hemostasis system, allowing for efficient workflow at the point of care.

Paul D. Thompson, MD, pens a column underlining the prevalence and impact of hemochromatosis on the health of patients based on current evidence.

Check out the latest cardiology case report from Brady Pregerson, MD. This case features a woman in her mid-50s presenting with generalized weakness, vomiting, and a 35-pound weight loss in the last 3 months. Can you determine the correct diagnosis?

Practical Cardiology has compiled a list of the 5 most popular stories of the past year to celebrate the end of 2021.

Manesh Patel, MD, and his colleague Rymer delve into the most impactful and interesting trials presented at the Fall cardiovascular meetings.

To celebrate the end of 2021, Practical Cardiology has created a list of the top FDA approvals from the past year based on popularity and relevance to current standards of care.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.

New research published in the Journal of the American Heart Association provides an overview of the changes in the rate of premature death due to acute myocardial infarction among patients in the US younger than 65 years of age.

Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.

Announced on Dec. 20, the US FDA awarded approval to the Sapien 3 with Alterra from Edwards Lifesciences Corporation for pediatric and adult patients with severe pulmonary regurgitation.

Announced on Dec. 20, the latest approvals for rivaroxaban (Xarelto) mark the 10th and 11th indications for the factor Xa inhibitor in the US.

The TPV system expands transcatheter therapy options for patients with congenital heart valve disease.

A recent study found the addition of LCE CT reportedly bolsters the diagnosis rate among patients with acute chest pain who have negative findings on TRO CT.

An analysis of data from the PURE study suggests those with high stress levels had a 22% greater risk of cardiovascular disease, a 24% greater risk of congestive heart disease, and a 30% greater risk of stroke compared to their counterparts with no stress.

Cardiologists have utilized new technologies during the COVID-19 pandemic.

Implicity announced their ILR ECG Analyzer received 510(k) clearance from the FDA in a statement released on December 16.